Humana's (HUM) Sell (D+) Rating Reaffirmed at Weiss Ratings

Key Points

• Humana's stock has been reaffirmed with a "sell (D+)" rating by Weiss Ratings, reflecting ongoing concerns from analysts regarding the company's performance.
• Barclays recently lowered their target price for Humana from $315.00 to $245.00, while the average price target among analysts stands at $296.06.
• Humana reported earnings of $6.27 per share for the last quarter, missing expectations slightly, and experienced a 9.6% increase in year-over-year revenue, totaling $32.39 billion.

Humana (NYSE:HUM - Get Free Report)'s stock had its "sell (d+)" rating reissued by research analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

HUM has been the subject of several other reports. Barclays dropped their target price on Humana from $315.00 to $245.00 and set an "equal weight" rating for the company in a report on Friday, October 3rd. Wall Street Zen cut Humana from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Royal Bank Of Canada increased their target price on Humana from $283.00 to $322.00 and gave the company an "outperform" rating in a report on Thursday, August 21st. Sanford C. Bernstein increased their price objective on Humana from $269.00 to $341.00 and gave the stock an "outperform" rating in a report on Friday, September 5th. Finally, Bank of America increased their price objective on Humana from $285.00 to $312.00 and gave the stock a "neutral" rating in a report on Tuesday, September 2nd. Seven research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $296.06.

Humana Trading Up 1.0%

Shares of HUM stock opened at $298.26 on Wednesday. The stock has a market capitalization of $35.87 billion, a PE ratio of 22.89, a P/E/G ratio of 1.73 and a beta of 0.42. Humana has a 1-year low of $206.87 and a 1-year high of $315.35. The business has a 50-day moving average of $277.98 and a 200 day moving average of $258.03. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95.

Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing the consensus estimate of $6.32 by ($0.05). The company had revenue of $32.39 billion for the quarter, compared to analysts' expectations of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The company's revenue was up 9.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, sell-side analysts anticipate that Humana will post 16.47 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in HUM. Cary Street Partners Investment Advisory LLC increased its holdings in shares of Humana by 63.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock worth $31,000 after purchasing an additional 46 shares in the last quarter. Applied Finance Capital Management LLC increased its holdings in shares of Humana by 1.7% in the 1st quarter. Applied Finance Capital Management LLC now owns 2,943 shares of the insurance provider's stock worth $779,000 after purchasing an additional 48 shares in the last quarter. Blue Trust Inc. increased its holdings in shares of Humana by 3.6% in the 2nd quarter. Blue Trust Inc. now owns 1,367 shares of the insurance provider's stock worth $334,000 after purchasing an additional 48 shares in the last quarter. Achmea Investment Management B.V. increased its holdings in shares of Humana by 0.5% in the 1st quarter. Achmea Investment Management B.V. now owns 10,379 shares of the insurance provider's stock worth $2,746,000 after purchasing an additional 49 shares in the last quarter. Finally, Beech Hill Advisors Inc. increased its holdings in shares of Humana by 6.1% in the 1st quarter. Beech Hill Advisors Inc. now owns 865 shares of the insurance provider's stock worth $229,000 after purchasing an additional 50 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.